You are here:

ombitasvir / paritaprevir ritonavir (Viekirax) and dasabuvir (Exviera)

Advice

following a full submission

This document includes advice on two products; ombitasvir/paritaprevir/ritonavir (Viekirax®) and dasabuvir (Exviera®).

ombitasvir/paritaprevir/ritonavir (Viekirax®) is accepted for use within NHS Scotland.

dasabuvir (Exviera®) is accepted for use within NHS Scotland.

Indications under review:
• Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with dasabuvir (Exviera®) with or without ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adults 

• Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with ribavirin for the treatment of genotype 4 CHC in adults 

In six phase III studies, conducted in patients with genotype 1 CHC, rates of sustained virological response at 12 weeks post-treatment were achieved in ≥96% of patients who received licensed treatment regimens of ombitasvir/paritaprevir/ritonavir + dasabuvir, irrespective of sub-genotype, previous treatment and presence of cirrhosis.
 

Drug Details

Drug Name: ombitasvir / paritaprevir ritonavir (Viekirax) and dasabuvir (Exviera)
SMC Drug ID: 1051/15
Manufacturer: AbbVie Ltd
Indication: Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with dasabuvir (Exviera®) with or without ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adults.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 June 2015

Back